Scarica l'app Stockscreener
1.87
4.10%
-0.08
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ACRS Giù?
Forum
Previsione
Precedente Chiudi:
$1.95
Aprire:
$1.97
Volume 24 ore:
580.89K
Relative Volume:
0.56
Capitalizzazione di mercato:
$202.58M
Reddito:
$27.08M
Utile/perdita netta:
$-37.00M
Rapporto P/E:
-3.5962
EPS:
-0.52
Flusso di cassa netto:
$-18.46M
1 W Prestazione:
+0.54%
1M Prestazione:
-8.33%
6M Prestazione:
+73.15%
1 anno Prestazione:
+61.21%
Intervallo 1D:
$1.855
$1.97
Intervallo di 1 settimana:
$1.84
$1.97
Portata 52W:
$1.05
$5.17
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Nome
Aclaris Therapeutics Inc
Settore
Industria
Telefono
484-324-7933
Indirizzo
701 LEE ROAD, WAYNE, PA
Confronta ACRS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
1.87 | 211.25M | 27.08M | -37.00M | -18.46M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-10 | Ripresa | Piper Sandler | Overweight |
| 2025-05-28 | Iniziato | Wedbush | Outperform |
| 2025-03-18 | Ripresa | Cantor Fitzgerald | Overweight |
| 2024-12-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2024-11-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-11-19 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | Iniziato | Evercore ISI | Outperform |
| 2022-12-14 | Iniziato | Stifel | Buy |
| 2022-12-01 | Iniziato | Goldman | Buy |
| 2022-10-06 | Iniziato | BTIG Research | Buy |
| 2021-07-23 | Ripresa | Jefferies | Buy |
| 2021-06-15 | Iniziato | Piper Sandler | Overweight |
| 2021-04-21 | Iniziato | H.C. Wainwright | Buy |
| 2019-10-22 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | Iniziato | SVB Leerink | Outperform |
| 2018-03-28 | Ripresa | Leerink Partners | Outperform |
| 2018-02-09 | Iniziato | Guggenheim | Buy |
| 2017-06-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2016-11-29 | Iniziato | Leerink Partners | Outperform |
| 2016-09-30 | Iniziato | JMP Securities | Mkt Outperform |
| 2016-06-10 | Iniziato | Guggenheim | Buy |
| 2015-11-02 | Iniziato | Citigroup | Buy |
| 2015-11-02 | Iniziato | Jefferies | Buy |
Mostra tutto
Aclaris Therapeutics Inc Borsa (ACRS) Ultime notizie
Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Invest In Growth? - Yahoo Finance
Building trade automation scripts for Aclaris Therapeutics Inc.2025 Trade Ideas & Weekly Momentum Picks - newser.com
Full technical analysis of Aclaris Therapeutics Inc. stock2025 Investor Takeaways & Real-Time Sentiment Analysis - newser.com
Real time alert setup for Aclaris Therapeutics Inc. performanceQuarterly Portfolio Review & Fast Exit and Entry Trade Guides - newser.com
Real time breakdown of Aclaris Therapeutics Inc. stock performanceJuly 2025 Technicals & Fast Exit and Entry Trade Guides - newser.com
Is Aclaris Therapeutics Inc. (8AT) stock testing key supportGDP Growth & Stock Portfolio Risk Control - newser.com
Atopic Dermatitis Pipeline Outlook Report 2025: Insight into emerging drugs, treatment options, clinical trials, and company strategies - The Globe and Mail
What analysts say about Aclaris Therapeutics Inc 8AT stockMarket Sentiment Shifts & Outperform the Market with Aggressive Picks - earlytimes.in
How Aclaris Therapeutics Inc. stock performs during Fed tightening cyclesEarnings Recap Report & Weekly Top Gainers Alerts - newser.com
Sentiment analysis tools applied to Aclaris Therapeutics Inc.July 2025 Catalysts & Risk Adjusted Buy/Sell Alerts - newser.com
Will Aclaris Therapeutics Inc. rebound enough to break evenRate Cut & High Accuracy Trade Signal Alerts - newser.com
Risk vs reward if holding onto Aclaris Therapeutics Inc.July 2025 Earnings & Reliable Volume Spike Alerts - newser.com
Real time scanner hits for Aclaris Therapeutics Inc. explainedCEO Change & Daily Stock Trend Reports - newser.com
Will Aclaris Therapeutics Inc. (8AT) stock profit from automation waveGold Moves & High Yield Equity Trading Tips - newser.com
Using fundamentals and technicals on Aclaris Therapeutics Inc.Weekly Market Report & High Yield Stock Recommendations - newser.com
Aclaris to Host 2025 R&D Day in New York to Spotlight Immuno-Inflammatory Pipeline - MyChesCo
Using Bollinger Bands to evaluate Aclaris Therapeutics Inc.July 2025 PostEarnings & High Yield Stock Recommendations - newser.com
How high can Aclaris Therapeutics Inc. stock goCPI Data & Free Community Supported Trade Ideas - newser.com
Will Aclaris Therapeutics Inc. (8AT) stock beat revenue estimatesWeekly Trade Review & Accurate Intraday Trade Tips - newser.com
Published on: 2025-10-02 23:56:18 - newser.com
What drives Aclaris Therapeutics Inc stock priceBreakout Stock Watch & Exceptional Return Investment - earlytimes.in
Does Aclaris Therapeutics Inc. qualify in momentum factor screeningWeekly Risk Summary & Precise Buy Zone Tips - newser.com
Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025 - Sahm
Aclaris Therapeutics to Host In-Person and Webcast R&D Day, "Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets", in New York on October 14, 2025 - Investing News Network
Aclaris Therapeutics to Host In-Person and Webcast R&D Day, 'Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025 - The Manila Times
Aclaris Therapeutics to Host In-Person and Webcast R&D Day, - GlobeNewswire
How to read the order book for Aclaris Therapeutics Inc.2025 Sector Review & Community Consensus Trade Alerts - newser.com
Aclaris Therapeutics Inc Azioni (ACRS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Aclaris Therapeutics Inc Azioni (ACRS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Mehra Anand | Director |
Nov 19 '24 |
Buy |
2.25 |
666,666 |
1,499,998 |
710,030 |
5.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):